Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Skin cancer drug rejection criticised

  • Comment

A skin cancer patient support group has condemned a decision to deny sufferers a “potentially life extending” new drug.

Factor 50 called for the National Institute for Health and Clinical Excellence (NICE) to reconsider its preliminary decision not to recommend the drug Vemurafenib.

The group said that the drug, also known as Zelboraf, was proven to prolong the lives of patients with advanced metastatic melanoma.

Chief executive officer Gill Nuttall said the decision was a “truly devastating blow” to patients, adding: “Standard treatments that have been available since the 1970s are ineffective and to deny this drug to patients, is tantamount to passing them a death sentence.

“I am astonished and deeply worried that Nice has not given approval to yet another drug which will significantly alter the lives of melanoma patients.”

Nice issued draft guidance not to recommend the drug, which costs about £1,750 a week, saying the long-term benefits of it were difficult to quantify because of the limitations of available evidence.

Sir Andrew Dillon, chief executive of NICE, said: “We need to be sure that new treatments provide sufficient benefits to patients to justify the significant cost the NHS is being asked to pay.

“Vemurafenib is an expensive drug and its long-term benefits are difficult to quantify.”

Manufacturers Roche said they were extremely disappointed with the decision.

Roche UK managing director John Melville said: “Zelboraf ticks all the boxes when considering the types of medicines that value-based pricing aims to encourage pharmaceutical companies to develop, and in addition we strongly believe it is cost effective.

“NICE themselves acknowledge that Zelboraf is innovative and addresses an unmet need.”

NICE has opened a public consultation on its guidance.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs